# K122961

# TABLE 4

1. Date:

November 1, 2012

2. Submitter:

Guangzhou Wondfo Biotech Co., Ltd. South China University of Technology Guangzhou, P.R. China 510641 012-86-20-32296069

3. Name of contact person:

Joe Shia LSI International Inc. 504 East Diamond Ave., Suite F Gaithersburg, MD 20878 Telephone: 240-505-7880 Fax: 301-916-6231 Email:shiajl@yahoo.com

4. Device Name:

Wondfo Amphetamine Urine Test (AMP 300) Wondfo Methamphetamine Urine Test (MET 500)

Classification: All are Class I medical devices with the following various product codes with Code of Federal Regulation references:

<table><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>CFR #</td></tr><tr><td rowspan=1 colspan=1>DKZ</td><td rowspan=1 colspan=1>21 CFR, 862.3100</td></tr><tr><td rowspan=1 colspan=1>LAF</td><td rowspan=1 colspan=1>21 CFR, 862.3610</td></tr></table>

Predicate Devices:

1. K041822 Acon Laboratories, Inc. ACON® AMP 300 One Step Amphetamine Test Strip, ACON® AMP 300 One Step Amphetarmine Test Device

2. K033299 Acon Laboratories, Inc. ACON® mAMP-500 One Step Methamphetamine Test Strip, ACON® mAMP-500 One Step Methamphetamine Test Device

# 6. Intended Use:

Wondfo Amphetamine Urine Test (AMP 300) and Wondfo Methamphetamine Urine Test (MET 500) are intended for the qualitative determination of d-Amphetamine and $\mathsf { D } ( + )$ Methamphetamine (target analyte) cucratn nn i ouc ine pepin is not intended for point-of-care use. For in vitro diagnostic use only.

7. Device Description:

Assay Principle: Immunochromatograph assay for Amphetamine and Methamphetamine Urine Test using a lateral flow, one step system for the qualitative detection of d-Amphetamine and $\mathsf { D } ( + ) -$ Methamphetamine (target analyte) in human urine. Each assay uses a monoclonal antibody-dye conjugate from mouse against drug with gold chloride and fixed drug-protein conjugate and anti-mouse IgG polyclonal antibody in membrane.

# 8. Substantial Equivalence Information

A summary comparison of the features of the Wondfo Amphetamine Urine Test (AMP 300) and Wondfo Methamphetamine Urine Test (MET 500) and the predicate devices is provided in the Table 1 & Table 2.

Table 1: Features Comparison of Wondfo Amphetamine Urine Test (AMP 300) and the Predicate Devices   

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate - K041822</td></tr><tr><td rowspan=1 colspan=1>Indication(s) forUse</td><td rowspan=1 colspan=1>For the qualitative determination of Amphetaminein human urine.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibrator</td><td rowspan=1 colspan=1>d-Amphetamine</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Methodology</td><td rowspan=1 colspan=1>Competitive binding, lateral flowimmunochromatographic assays based on theprinciple of antigen antibody immunochemistry.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Type of Test</td><td rowspan=1 colspan=1>Immunoassay principles that rely on antigen-antibody interactions to indicate positive ornegative result</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Specimen Type</td><td rowspan=1 colspan=1>Human Urine</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Cut Off Values</td><td rowspan=1 colspan=1>300 ng/mL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Configurations</td><td rowspan=1 colspan=1>Cup, Dip Card</td><td rowspan=1 colspan=1>Strip, Device</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Prescription Use and not for point-of-care use</td><td rowspan=1 colspan=1>Prescription Use andfor point-of-care use</td></tr></table>

Table 2: Features Comparison of Wondfo Methamphetamine Urine Test (MET 500) and the Predicate Devices   

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate - K033299-</td></tr><tr><td rowspan=1 colspan=1>Indication(s) forUse</td><td rowspan=1 colspan=1>For the qualitative determination of D(+)-Methamphetamine in human urine.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibrator</td><td rowspan=1 colspan=1>D(+)-Methamphetamine</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Methodology</td><td rowspan=1 colspan=1>Competitive binding, lateral flowimmunochromatographic assays based on theprinciple of antigen antibody immunochemistry.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Type of Test</td><td rowspan=1 colspan=1>Immunoassay principles that rely on antigen-antibody interactions to indicate positive ornegative result</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Specimen Type</td><td rowspan=1 colspan=1>Human Urine</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Cut Off Values</td><td rowspan=1 colspan=1>500 ng/mL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Configurations</td><td rowspan=1 colspan=1>Cup, Dip Card</td><td rowspan=1 colspan=1>Strip, Device</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Prescription Use and not for point-of-care use</td><td rowspan=1 colspan=1>Prescription Use and forpoint-of-care use</td></tr></table>

# 9. Standard/Guidance Document Reference

Baselt, R.C. Disposition of Toxic Drugs and Chemicals in Man. Biomedical Publications, Davis, CA, 1982.   
Ellenhorn, M.J. and Barceloux, D. G Medical Toxicology. Elservier Science Publishing Company, Inc., New York, 1988   
Gilman, A. G., and Goodman, L. S. The Pharmacological Fluids, in Martin WR(ed): Drug Addiction I, New York, Spring - Verlag, 1977.   
Harvey, R.A., Champe, P.C. Lippincotts Ilustrated Reviews. Pharmacology. 91-95, 1992.   
Hawwks RL, CN Chiang. Urine Testing for drugs of Abuse. National Institute for Drug Abuse (NIDA), Research Monography 73, 1986   
Hofmann F.E., A Handbook on Drug and Alcohol Abuse: The Biomedical Aspects, New York, Oxford University Press, 1983.   
•McBay, A. J. Clin. Chem. 33,33B-40B, 1987

# 10. Test Principle

Wondfo Amphetamine Urine Test (AMP 300) and Wondfo Methamphetamine Urine Test (MET 500) are a one-step lateral flow immunoassay containing a conjugate pad with colloidal gold with anti-drug antibodies, a nitrocellulose membrane, with a test line $( \mathsf { T } )$ and a control line (C). The T line is coated with drug-protein conjugate and the C lne is coated with goat anti-mouse IgG polyclonalantibodies. The test is a competitive binding immunoassay in which drugs in a urine sample compete with immobilized drug conjugatefor limited labeled antibody binding sites. When a sufficient amount f sample isapplied, the sample migrates through the test device by capillary action.

If the concentration of drug is below the cutoff level, the anti-drug antibodies in the colloidal gold particles wll bind to the drug antigens coated in the test zone producing a band which indicates a e l ill e (et ne T) indicating a prelminary positive.A band should form n the control regin regardlesse presence of drug or metabolite in the sample.

# 11. Performance Characteristics

# 11.1. Analytical Performance

# a. Precision

Precision studies were carried out for samples with concentrations of $. 100 \%$ cut off, -75%cut off, - $50 \%$ cut off, $2 5 \%$ cut off, $+ 2 5 \%$ cut off, $+ 5 0 \%$ cut off , $+ 7 5 \%$ cut off and $+ 1 0 0 \%$ cut off. For each concentration, tests were performed two runs per day for 25 days. The results obtained are summarized in the following table.

# Cup Format

AMP 300:   

<table><tr><td rowspan=1 colspan=1>ResuitAMP 300</td><td rowspan=1 colspan=1>-100%cut off</td><td rowspan=1 colspan=1>-75%cut off</td><td rowspan=1 colspan=1>-50%cut off</td><td rowspan=1 colspan=1>-25%Cut off</td><td rowspan=1 colspan=1>cut off</td><td rowspan=1 colspan=1>+25%cut off</td><td rowspan=1 colspan=1>+50%cut off</td><td rowspan=1 colspan=1>+75%cut off</td><td rowspan=1 colspan=1>+100%cut off</td></tr><tr><td rowspan=1 colspan=1>LOT W0770901CU2</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>47+/3-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>LOT W0770902CU2</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>45+/5-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>LOT W0770903CU2</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>45+/5-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr></table>

MET 500:   
Dip Card Format   

<table><tr><td rowspan=1 colspan=1>ResultMET 500</td><td rowspan=1 colspan=1>-100%cut off</td><td rowspan=1 colspan=1>-75%cut off</td><td rowspan=1 colspan=1>-50%cut off</td><td rowspan=1 colspan=1>-25%Cut off</td><td rowspan=1 colspan=1>cut off</td><td rowspan=1 colspan=1>+25%cut off</td><td rowspan=1 colspan=1>+50%cut off</td><td rowspan=1 colspan=1>+75%cut off</td><td rowspan=1 colspan=1>+100%cut off</td></tr><tr><td rowspan=1 colspan=1>LOT W1170901CU2</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>45+/5-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>LOT W1170902CU2</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>46+/4-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>LOT W1170903CU2</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>46+/4-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr></table>

AMP 300:   

<table><tr><td colspan="1" rowspan="1">ResultAMP 300</td><td colspan="1" rowspan="1">-100%cut off</td><td colspan="1" rowspan="1">-75%cut off</td><td colspan="1" rowspan="1">-50%cut off</td><td colspan="1" rowspan="1">-25%cut off</td><td colspan="1" rowspan="1">cut off</td><td colspan="1" rowspan="1">+25%cut off</td><td colspan="1" rowspan="1">+50%cut off</td><td colspan="1" rowspan="1">+75%cut off</td><td colspan="1" rowspan="1">+100%cut off</td></tr><tr><td colspan="1" rowspan="1">LOT W0770901P</td><td colspan="1" rowspan="1">50-/0+</td><td colspan="1" rowspan="1">50-/0+</td><td colspan="1" rowspan="1">50-/0+</td><td colspan="1" rowspan="1">50-/0+</td><td colspan="1" rowspan="1">44+/6-</td><td colspan="1" rowspan="1">50+/0-</td><td colspan="1" rowspan="1">50+/0-</td><td colspan="1" rowspan="1">50+/0-</td><td colspan="1" rowspan="1">50+/0-</td></tr><tr><td colspan="1" rowspan="1">LOT W0770902P</td><td colspan="1" rowspan="1">50-/0+</td><td colspan="1" rowspan="1">50-/0+</td><td colspan="1" rowspan="1">50-0+</td><td colspan="1" rowspan="1">50-/0+</td><td colspan="1" rowspan="1">45+/5-</td><td colspan="1" rowspan="1">50+/0-</td><td colspan="1" rowspan="1">50+/0-</td><td colspan="1" rowspan="1">50+/0-</td><td colspan="1" rowspan="1">50+/0-</td></tr><tr><td colspan="1" rowspan="1">LOT W0770903P</td><td colspan="1" rowspan="1">50-/0+</td><td colspan="1" rowspan="1">50-/0+</td><td colspan="1" rowspan="1">50-/0+</td><td colspan="1" rowspan="1">50-/0+</td><td colspan="1" rowspan="1">46+/4-</td><td colspan="1" rowspan="1">50+/0-</td><td colspan="1" rowspan="1">50+/0-</td><td colspan="1" rowspan="1">50+/0-</td><td colspan="1" rowspan="1">50+/0-</td></tr><tr><td>Result</td><td>-100%</td><td>-75%</td><td>-50%</td><td>-25%</td><td>cut off</td><td>+25%</td><td>+50%</td><td>+75%</td><td>+100%</td></tr><tr><td>MET 500</td><td>cut off</td><td>cut off</td><td>cut off</td><td>cut off</td><td></td><td>cut off</td><td>cut off</td><td>cut off</td><td>cut off</td></tr><tr><td>LOT W1170901P</td><td>50-/0+</td><td>50-/0+</td><td>50-/0+</td><td>50-/0+</td><td>46+/4-</td><td>50+/0-</td><td>50+/0-</td><td>50+/0-</td><td>50+/0-</td></tr><tr><td>LOT W1170902P</td><td>50-/0+</td><td>50-/0+</td><td>50-/0+</td><td>50-/0+</td><td>44+/6-</td><td>50+/0-</td><td>50+/0-</td><td>50+/0-</td><td>50+/0-</td></tr><tr><td>LOT W1170903P</td><td>50-/0+</td><td>50-/0+</td><td>50-/0+</td><td>50-/0+</td><td>45+/5-</td><td>50+/0-</td><td>50+/0-</td><td>50+/0-</td><td>50+/0-</td></tr></table>

b. Linearity Not applicable

c. Stability Stable for 18 months when stored at 4 to $3 0 ~ \textdegree$ .

# d. Cut-off

<table><tr><td rowspan=1 colspan=1>Test</td><td rowspan=1 colspan=1>Calibrator</td><td rowspan=1 colspan=1>Cut-off (ng/mL)</td></tr><tr><td rowspan=1 colspan=1>Wondfo Amphetamine Urine Test (AMP 300)</td><td rowspan=1 colspan=1>d-Amphetamine</td><td rowspan=1 colspan=1>300</td></tr><tr><td rowspan=1 colspan=1>Wondfo Methamphetamine Urine Test (MET 500)</td><td rowspan=1 colspan=1>D(+)-Methamphetamine</td><td rowspan=1 colspan=1>500</td></tr></table>

# e. Interference

Compounds that show no interference at a concentration of $1 0 0 \mu g / m L$ are summarized in the following tables.

AMP 300   

<table><tr><td colspan="1" rowspan="1">4-Acetamidophenol</td><td colspan="1" rowspan="1">(-) Y Ephedrine</td><td colspan="1" rowspan="1">Penicillin-G</td></tr><tr><td colspan="1" rowspan="1">Acetophenetidin</td><td colspan="1" rowspan="1">Erythromycin</td><td colspan="1" rowspan="1">Pentazocaine</td></tr><tr><td colspan="1" rowspan="1">N-Acetylprocainamide</td><td colspan="1" rowspan="1">β-Estradiol</td><td colspan="1" rowspan="1">Pentobarbital</td></tr><tr><td colspan="1" rowspan="1">Acetylsalicylic acid</td><td colspan="1" rowspan="1">Estrone-3-sulfate</td><td colspan="1" rowspan="1">Perphenazine</td></tr><tr><td colspan="1" rowspan="1">Aminopyrine</td><td colspan="1" rowspan="1">Ethyl-p-aminobenzoate</td><td colspan="1" rowspan="1">Phencyclidine</td></tr><tr><td colspan="1" rowspan="1">Amitryptyline</td><td colspan="1" rowspan="1">Fenfluramine</td><td colspan="1" rowspan="1">Phenelzine</td></tr><tr><td colspan="1" rowspan="1">Amobarbital</td><td colspan="1" rowspan="1">Fenoprofen</td><td colspan="1" rowspan="1">Phendimetrazine</td></tr><tr><td colspan="1" rowspan="1">Amoxicillin</td><td colspan="1" rowspan="1">Furosemide</td><td colspan="1" rowspan="1">Phenobarbital</td></tr><tr><td colspan="1" rowspan="1">Ampicillin</td><td colspan="1" rowspan="1">Gentisic acid</td><td colspan="1" rowspan="1">Phetoin</td></tr><tr><td colspan="1" rowspan="1">Ascorbic acid</td><td colspan="1" rowspan="1">Hemoglobin</td><td colspan="1" rowspan="1">L-Phenylephrine</td></tr><tr><td colspan="1" rowspan="1">Apomorphine</td><td colspan="1" rowspan="1">Hydralazine</td><td colspan="1" rowspan="1">β-Phenylethlamine</td></tr><tr><td colspan="1" rowspan="1">Aspartame</td><td colspan="1" rowspan="1">Hydrochlorothiazide</td><td colspan="1" rowspan="1">Phenylpropanolamine</td></tr><tr><td colspan="1" rowspan="1">Atropine</td><td colspan="1" rowspan="1">Hydrocodone</td><td colspan="1" rowspan="1">Prednisolone</td></tr><tr><td colspan="1" rowspan="1">Benzilic acid</td><td colspan="1" rowspan="1">Hydrocortisone</td><td colspan="1" rowspan="1">Prednisone</td></tr><tr><td colspan="1" rowspan="1">Benzoic acid</td><td colspan="1" rowspan="1">O-Hydroxyhippuric acid</td><td colspan="1" rowspan="1">Procaine</td></tr><tr><td colspan="1" rowspan="1">Benzoylecgonine</td><td colspan="1" rowspan="1">3-Hydroxytyramine</td><td colspan="1" rowspan="1">Promazine</td></tr><tr><td colspan="1" rowspan="1">Bilirubin</td><td colspan="1" rowspan="1">Ibuprofen</td><td colspan="1" rowspan="1">Promethazine</td></tr><tr><td colspan="1" rowspan="1">Brompheniramine</td><td colspan="1" rowspan="1">Imipramine</td><td colspan="1" rowspan="1">D,L-Propanolol</td></tr><tr><td colspan="1" rowspan="1">Caffeine</td><td colspan="1" rowspan="1">(-) Isoproterenol</td><td colspan="1" rowspan="1">Propiomazine</td></tr><tr><td colspan="1" rowspan="1">Cannabidiol</td><td colspan="1" rowspan="1">Isoxsuprine</td><td colspan="1" rowspan="1">D-Propoxyphene</td></tr><tr><td colspan="1" rowspan="1">Cannabinol</td><td colspan="1" rowspan="1">Ketamine</td><td colspan="1" rowspan="1">Quinidine</td></tr><tr><td colspan="1" rowspan="1">Chloralhydrate</td><td colspan="1" rowspan="1">Ketoprofen</td><td colspan="1" rowspan="1">Quinine</td></tr><tr><td colspan="1" rowspan="1">Chloramphenicol</td><td colspan="1" rowspan="1">Labetalol</td><td colspan="1" rowspan="1">Ranitidine</td></tr><tr><td colspan="1" rowspan="1">Chlordiazepoxide</td><td colspan="1" rowspan="1">Levorphanol</td><td colspan="1" rowspan="1">Salicylic acid</td></tr><tr><td colspan="1" rowspan="1">Chlorothiazide</td><td colspan="1" rowspan="1">Loperamide</td><td colspan="1" rowspan="1">Secobarbital</td></tr><tr><td colspan="1" rowspan="1">)Chlorpheniramine</td><td colspan="1" rowspan="1">Maprotiline</td><td colspan="1" rowspan="1">Serotonin</td></tr><tr><td colspan="1" rowspan="1">Chlorpromazine</td><td colspan="1" rowspan="1">Meperidine</td><td colspan="1" rowspan="1">Sulfamethazine</td></tr><tr><td colspan="1" rowspan="1">Chlorquine</td><td colspan="1" rowspan="1">Meprobamate</td><td colspan="1" rowspan="1">Sulindac</td></tr><tr><td colspan="1" rowspan="1">Cholesterol</td><td colspan="1" rowspan="1">Methadone</td><td colspan="1" rowspan="1">Temazepam</td></tr><tr><td colspan="1" rowspan="1">Clomipramine</td><td colspan="1" rowspan="1">Methylphenidate</td><td colspan="1" rowspan="1">Tetracycline</td></tr><tr><td colspan="1" rowspan="1">Clonidine</td><td colspan="1" rowspan="1">Morphine-3-Dglucuronide</td><td colspan="1" rowspan="1">Tetrahydrocortisone</td></tr><tr><td colspan="1" rowspan="1">Cocaine hydrochloride</td><td colspan="1" rowspan="1">Nalidixic acid</td><td colspan="1" rowspan="1">Tetrahydrozoline</td></tr><tr><td colspan="1" rowspan="1">Codeine</td><td colspan="1" rowspan="1">Naloxone</td><td colspan="1" rowspan="1">49-THC-COOH</td></tr><tr><td colspan="1" rowspan="1">Cortisone</td><td colspan="1" rowspan="1">Naltrexone</td><td colspan="1" rowspan="1">Thebaine</td></tr><tr><td colspan="1" rowspan="1">() Cotinine</td><td colspan="1" rowspan="1">Naproxen</td><td colspan="1" rowspan="1">Thiamine</td></tr><tr><td colspan="1" rowspan="1">Creatinine</td><td colspan="1" rowspan="1">Niacinamide</td><td colspan="1" rowspan="1">Thioridazine</td></tr><tr><td colspan="1" rowspan="1">Deoxycorticosterone</td><td colspan="1" rowspan="1">Nifedipine</td><td colspan="1" rowspan="1">D,L-Thyroxine</td></tr><tr><td colspan="1" rowspan="1">Dextromethorphan</td><td colspan="1" rowspan="1">Norcodein</td><td colspan="1" rowspan="1">Tolbutamine</td></tr><tr><td colspan="1" rowspan="1">Diazepam</td><td colspan="1" rowspan="1">Norethindrone</td><td colspan="1" rowspan="1">Triamterene</td></tr><tr><td colspan="1" rowspan="1">Diclofenac</td><td colspan="1" rowspan="1">D-Norpropoxyphene</td><td colspan="1" rowspan="1">Trifluoperazine</td></tr><tr><td colspan="1" rowspan="1">Diflunisal</td><td colspan="1" rowspan="1">Noscapine</td><td colspan="1" rowspan="1">Trimethoprim</td></tr><tr><td colspan="1" rowspan="1">Digoxin</td><td colspan="1" rowspan="1">D.L-Octopamine</td><td colspan="1" rowspan="1">Trimipramine</td></tr><tr><td colspan="1" rowspan="1">Diphenhydramine</td><td colspan="1" rowspan="1">Oxalic acid</td><td colspan="1" rowspan="1">Tryptamine</td></tr><tr><td colspan="1" rowspan="1">Doxylamine</td><td colspan="1" rowspan="1">Oxazepam</td><td colspan="1" rowspan="1">D, L-Tyrosine</td></tr><tr><td colspan="1" rowspan="1">Ecgonine hydrochloride</td><td colspan="1" rowspan="1">Oxolinic acid</td><td colspan="1" rowspan="1">Uric acid</td></tr><tr><td colspan="1" rowspan="1">Ecgonine methylester</td><td colspan="1" rowspan="1">Oxycodone</td><td colspan="1" rowspan="1">Verapamil</td></tr><tr><td colspan="1" rowspan="1">(IR,2S)-(-)-Ephedrine</td><td colspan="1" rowspan="1">Oxymetazoline</td><td colspan="1" rowspan="1">Zomepirac</td></tr><tr><td colspan="1" rowspan="1">L-Ephedrine</td><td colspan="1" rowspan="1">Papaverine</td><td colspan="1" rowspan="1"></td></tr></table>

MET 500   

<table><tr><td rowspan=1 colspan=3>MET 500</td></tr><tr><td rowspan=1 colspan=1>Acetamidophen</td><td rowspan=1 colspan=1>Gentisic acid</td><td rowspan=1 colspan=1>Oxycodone</td></tr><tr><td rowspan=1 colspan=1>Acetophenetidin</td><td rowspan=1 colspan=1>Glucuronide</td><td rowspan=1 colspan=1>Oxymetazoline</td></tr><tr><td rowspan=1 colspan=1>N-Acetylprocainamide</td><td rowspan=1 colspan=1>Glutethimide</td><td rowspan=1 colspan=1>Papaverine</td></tr><tr><td rowspan=1 colspan=1>AcetyIsalicylate</td><td rowspan=1 colspan=1>Guaifenesin</td><td rowspan=1 colspan=1>Penicillin-G</td></tr><tr><td rowspan=1 colspan=1>Aminopyrine</td><td rowspan=1 colspan=1>Hippuric acid</td><td rowspan=1 colspan=1>Pentazocine</td></tr><tr><td rowspan=1 colspan=1>Amitryptyline</td><td rowspan=1 colspan=1>Hydralazine</td><td rowspan=1 colspan=1>Pentobarbital</td></tr><tr><td rowspan=1 colspan=1>Amobarbital</td><td rowspan=1 colspan=1>Hydrochlorothiazide</td><td rowspan=1 colspan=1>Perphenazine</td></tr><tr><td rowspan=1 colspan=1>Amoxicillin</td><td rowspan=1 colspan=1>Hydrocodone</td><td rowspan=1 colspan=1>Phencyclidine</td></tr><tr><td rowspan=1 colspan=1>Ampicillin</td><td rowspan=1 colspan=1>Hydrocortisone</td><td rowspan=1 colspan=1>Phenelzine</td></tr><tr><td rowspan=1 colspan=1>Apomorphine</td><td rowspan=1 colspan=1>O-Hydroxyhippuric acid</td><td rowspan=1 colspan=1>Phenobarbital</td></tr><tr><td rowspan=1 colspan=1>Aspartame</td><td rowspan=1 colspan=1>3-Hydroxytyramine</td><td rowspan=1 colspan=1>Prednisolone</td></tr><tr><td rowspan=1 colspan=1>Atropine</td><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>Phenylpropanolamine</td></tr><tr><td rowspan=1 colspan=1>Benzilic acid</td><td rowspan=1 colspan=1>Imipramine</td><td rowspan=1 colspan=1>Prednisone</td></tr><tr><td rowspan=1 colspan=1>Benzoic acid</td><td rowspan=1 colspan=1>() Isoproterenol</td><td rowspan=1 colspan=1>Procaine</td></tr><tr><td rowspan=1 colspan=1>Benzoylecgonine</td><td rowspan=1 colspan=1>Isoxsuprine</td><td rowspan=1 colspan=1>Promazine</td></tr><tr><td rowspan=1 colspan=1>Butabartital</td><td rowspan=1 colspan=1>Ketamine</td><td rowspan=1 colspan=1>Promethazine</td></tr><tr><td rowspan=1 colspan=1>Cannabidiol</td><td rowspan=1 colspan=1>Ketoprofen</td><td rowspan=1 colspan=1>D,L-Propanolol</td></tr><tr><td rowspan=1 colspan=1>Chloralhydrate</td><td rowspan=1 colspan=1>Labetalol</td><td rowspan=1 colspan=1>D-Propoxyphene</td></tr><tr><td rowspan=1 colspan=1>Chloramphenicol</td><td rowspan=1 colspan=1>Levorphanol</td><td rowspan=1 colspan=1>D-Pseudoephedrine</td></tr><tr><td rowspan=1 colspan=1>Chlordiazepoxide</td><td rowspan=1 colspan=1>Loperamide</td><td rowspan=1 colspan=1>Quinidine</td></tr><tr><td rowspan=1 colspan=1>Chlorothiazide</td><td rowspan=1 colspan=1>Loxapine succinate</td><td rowspan=1 colspan=1>Quinine</td></tr><tr><td rowspan=1 colspan=1>Chlorpromazine</td><td rowspan=1 colspan=1>Maprotiline</td><td rowspan=1 colspan=1>Ranitidine</td></tr><tr><td rowspan=1 colspan=1>Cholesterol</td><td rowspan=1 colspan=1>Meperidine</td><td rowspan=1 colspan=1>Salicylic acid</td></tr><tr><td rowspan=1 colspan=1>Clomipramine</td><td rowspan=1 colspan=1>Meprobamate</td><td rowspan=1 colspan=1>Secobarbital</td></tr><tr><td rowspan=1 colspan=1>Clonidine</td><td rowspan=1 colspan=1>Methadone</td><td rowspan=1 colspan=1>Serotonin (5- Hydroxytyramine)</td></tr><tr><td rowspan=1 colspan=1>Cocaine hydrochloride</td><td rowspan=1 colspan=1>Methaqualone</td><td rowspan=1 colspan=1>Sulfamethazine</td></tr><tr><td rowspan=1 colspan=1>Codeine</td><td rowspan=1 colspan=1>Methylphenidal</td><td rowspan=1 colspan=1>Sulindac</td></tr><tr><td rowspan=1 colspan=1>Cortisone</td><td rowspan=1 colspan=1>Methyprylon</td><td rowspan=1 colspan=1>Temazepam</td></tr><tr><td rowspan=1 colspan=1>(-) Cotinine</td><td rowspan=1 colspan=1>Morphine-3-β-Dglucuronide</td><td rowspan=1 colspan=1>Tetracycline</td></tr><tr><td rowspan=1 colspan=1>Creatinine</td><td rowspan=1 colspan=1>Nalidixic acid</td><td rowspan=1 colspan=1>Tetrahydrocortisone, 3-Acetate</td></tr><tr><td rowspan=1 colspan=1>Deoxycorticosterone</td><td rowspan=1 colspan=1>Nalorphine</td><td rowspan=1 colspan=1>Tetrahydrocortisone 3 (β-D glucuronide)</td></tr><tr><td rowspan=1 colspan=1>Dextromethorphan</td><td rowspan=1 colspan=1>Naloxone</td><td rowspan=1 colspan=1>Tetrahydrozoline</td></tr><tr><td rowspan=1 colspan=1>Diazepam</td><td rowspan=1 colspan=1>Naltrexone</td><td rowspan=1 colspan=1>Thebaine</td></tr><tr><td rowspan=1 colspan=1>Diclofenac</td><td rowspan=1 colspan=1>Naproxen</td><td rowspan=1 colspan=1>Thiamine</td></tr><tr><td rowspan=1 colspan=1>Diflunisal</td><td rowspan=1 colspan=1>Niacinamide</td><td rowspan=1 colspan=1>Thioridazine</td></tr><tr><td rowspan=1 colspan=1>Digoxin</td><td rowspan=1 colspan=1>Nifedipine</td><td rowspan=1 colspan=1>Tolbutamine</td></tr><tr><td rowspan=1 colspan=1>Diphenhydramine</td><td rowspan=1 colspan=1>Norcodein</td><td rowspan=1 colspan=1>Triamterene</td></tr><tr><td rowspan=1 colspan=1>Doxylamine</td><td rowspan=1 colspan=1>Norethindrone</td><td rowspan=1 colspan=1>Trifluoperazine</td></tr><tr><td rowspan=1 colspan=1>Ecgonine hydrochloride</td><td rowspan=1 colspan=1>Noroxymorphone</td><td rowspan=1 colspan=1>Trimethoprim</td></tr><tr><td rowspan=1 colspan=1>Ecgonine methyl ester</td><td rowspan=1 colspan=1>D-Norpropoxyphene</td><td rowspan=1 colspan=1>Trimipramine</td></tr><tr><td rowspan=1 colspan=1>Erythromycin</td><td rowspan=1 colspan=1>Noscapine</td><td rowspan=1 colspan=1>D, L-Tryptophan</td></tr><tr><td rowspan=1 colspan=1>β-Estradiol</td><td rowspan=1 colspan=1>Nylidrin</td><td rowspan=1 colspan=1>Tyramine</td></tr><tr><td rowspan=1 colspan=1>Estrone-3-sulfate</td><td rowspan=1 colspan=1>D,L-Octopamine</td><td rowspan=1 colspan=1>D. L-Tyrosine</td></tr><tr><td rowspan=1 colspan=1>Ethyl-p-aminobenzoate</td><td rowspan=1 colspan=1>Oxalic acid</td><td rowspan=1 colspan=1>Uric acid</td></tr><tr><td rowspan=1 colspan=1>Fenoprofen</td><td rowspan=1 colspan=1>Oxazepam</td><td rowspan=1 colspan=1>Verapamil</td></tr><tr><td rowspan=1 colspan=1>Furosemide</td><td rowspan=1 colspan=1>Oxolinic acid</td><td rowspan=1 colspan=1>Zomepirac</td></tr></table>

# f. Specificity

To test the specificity, target drug,drug metabolites and other components that ae likely to be prent in urine samples were tested Compounds that produced positive results with the test when tested at levels l greatr han heconcnratins s belowerent croseactivity cpn  clu bydiviighe uocntration by theinu cncnration equi tobta a positiesul an multiplying by $100 \%$ .

AMP 300   

<table><tr><td rowspan=1 colspan=1>AMP(Amphetamine)(d-Amphetamine, Cutoff=300 ng/mL)</td><td rowspan=1 colspan=1>Minimum concentrationrequired to obtain a positiveresult (ng/mL)</td><td rowspan=1 colspan=1>% Cross-Reactivity</td></tr><tr><td rowspan=1 colspan=1>d-Amphetamine</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>I-Amphetamine</td><td rowspan=1 colspan=1>17500</td><td rowspan=1 colspan=1>1.7%</td></tr><tr><td rowspan=1 colspan=1>dI-Amphetamine</td><td rowspan=1 colspan=1>850</td><td rowspan=1 colspan=1>35.3%</td></tr><tr><td rowspan=1 colspan=1>(+/-) 3,4-methylenedioxyamphetamine (MDA)</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>30.0%</td></tr><tr><td rowspan=1 colspan=1>Phentermine</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>30.0%</td></tr><tr><td rowspan=1 colspan=1>β-Phenylethylamine</td><td rowspan=1 colspan=1>100000</td><td rowspan=1 colspan=1>0.3%</td></tr><tr><td rowspan=1 colspan=1>Tyramine</td><td rowspan=1 colspan=1>100000</td><td rowspan=1 colspan=1>0.3%</td></tr><tr><td rowspan=1 colspan=1>p-Hydroxynorephedrine</td><td rowspan=1 colspan=1>100000</td><td rowspan=1 colspan=1>0.3%</td></tr><tr><td rowspan=1 colspan=1>PhenyIpropanolamine</td><td rowspan=1 colspan=1>&gt;100,000</td><td rowspan=1 colspan=1>Not detected</td></tr><tr><td rowspan=1 colspan=1>(t)Phenylpropanolamine</td><td rowspan=1 colspan=1>&gt;100,000</td><td rowspan=1 colspan=1>Not detected</td></tr><tr><td rowspan=1 colspan=1>p-Hydroxyamphetamine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>0.3%</td></tr><tr><td rowspan=1 colspan=1>d/l-Norephedrine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>0.3%</td></tr><tr><td rowspan=1 colspan=1>d-Methamphetamine</td><td rowspan=1 colspan=1>&gt;100,000</td><td rowspan=1 colspan=1>Not detected</td></tr><tr><td rowspan=1 colspan=1>I-Methamphetamine</td><td rowspan=1 colspan=1>&gt;100,000</td><td rowspan=1 colspan=1>Not detected</td></tr><tr><td rowspan=1 colspan=1>(+/-)3,4-Methylenedioxyethylamphetamine(MDE)</td><td rowspan=1 colspan=1>&gt;100,000</td><td rowspan=1 colspan=1>Not detected</td></tr><tr><td rowspan=1 colspan=1>(+/-)3,4-Methylenedioxymethamphetamine(MDMA)</td><td rowspan=1 colspan=1>&gt;100,000</td><td rowspan=1 colspan=1>Not detected</td></tr><tr><td rowspan=1 colspan=1>Benzphetamine</td><td rowspan=1 colspan=1>&gt;100,000</td><td rowspan=1 colspan=1>Not detected</td></tr><tr><td rowspan=1 colspan=1>Ephedrine</td><td rowspan=1 colspan=1>&gt;100,000</td><td rowspan=1 colspan=1>Not detected</td></tr><tr><td rowspan=1 colspan=1>I-Ephedrine</td><td rowspan=1 colspan=1>&gt;100,000</td><td rowspan=1 colspan=1>Not detected</td></tr><tr><td rowspan=1 colspan=1>I-Epinephrine</td><td rowspan=1 colspan=1>&gt;100,000</td><td rowspan=1 colspan=1>Not detected</td></tr><tr><td rowspan=1 colspan=1>d/l-Epinephrine</td><td rowspan=1 colspan=1>&gt;100,000</td><td rowspan=1 colspan=1>Not detected</td></tr></table>

MET 500   

<table><tr><td colspan="1" rowspan="1">MET(Methamphetamine)(D(+)-Methamphetamine, Cutoff=500 ng/mL)</td><td colspan="1" rowspan="1">Minimum concentrationrequired to obtain a positiveresult (ng/mL)</td><td colspan="1" rowspan="1">% Cross-Reactivity</td></tr><tr><td colspan="1" rowspan="1">D(+)-Methamphetamine</td><td colspan="1" rowspan="1">500</td><td colspan="1" rowspan="1">100%</td></tr><tr><td colspan="1" rowspan="1">D-Amphetamine</td><td colspan="1" rowspan="1">50000</td><td colspan="1" rowspan="1">1.0%</td></tr><tr><td colspan="1" rowspan="1">Chloroquine</td><td colspan="1" rowspan="1">10000</td><td colspan="1" rowspan="1">5.0%</td></tr><tr><td colspan="1" rowspan="1">(+/-)-Ephedrine</td><td colspan="1" rowspan="1">25000</td><td colspan="1" rowspan="1">2.0%</td></tr><tr><td colspan="1" rowspan="1">(-)-Methamphetamine</td><td colspan="1" rowspan="1">10000</td><td colspan="1" rowspan="1">5.0%</td></tr><tr><td colspan="1" rowspan="1">(+1-)3,4-methylenedioxumethamphetamine(MDMA)</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">50.0%</td></tr><tr><td colspan="1" rowspan="1">β-Phenylethylamine</td><td colspan="1" rowspan="1">25000</td><td colspan="1" rowspan="1">2.0%</td></tr><tr><td colspan="1" rowspan="1">Trimethobenzamide</td><td colspan="1" rowspan="1">5000</td><td colspan="1" rowspan="1">10.0%</td></tr><tr><td colspan="1" rowspan="1">d/I-Amphetamine</td><td colspan="1" rowspan="1">75,000</td><td colspan="1" rowspan="1">0.7%</td></tr><tr><td colspan="1" rowspan="1">p-Hydroxymethamphetamine</td><td colspan="1" rowspan="1">115,00</td><td colspan="1" rowspan="1">3.3%</td></tr><tr><td colspan="1" rowspan="1">Mephentermine</td><td colspan="1" rowspan="1">25,000</td><td colspan="1" rowspan="1">2.0%</td></tr><tr><td colspan="1" rowspan="1">(1R,2S)-(-)-Ephedrine</td><td colspan="1" rowspan="1">50,000</td><td colspan="1" rowspan="1">1.0%</td></tr><tr><td colspan="1" rowspan="1">I-Phenylephrine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">0.5%</td></tr></table>

# 11.2. Comparison Studies

The method comparison for the Wondfo Amphetamine Urine Test (AMP 300), Wondfo Methamphetamine Urine Test (MET 500) were performed in-house with three laboratory assistants with relevant experience reading the instructions for use. Operators ran 80 (40 negative and 40 positive) unaltered clinical samples. The samples were blind labeled and compared to GC/MS results. The results are presented in the table below:

# AMP 300:

# Cup Format

<table><tr><td rowspan=1 colspan=2>Wondfo Result</td><td rowspan=1 colspan=1>Drug-free</td><td rowspan=1 colspan=1>Low Negative byCI/MS(Less than -50%)</td><td rowspan=1 colspan=1>Near CutoffNegative byGC/MS(Between -50%and Cutoff)</td><td rowspan=1 colspan=1>Near CutoffPositive byGC/MS(Between theCutoff and +50%)</td><td rowspan=1 colspan=1>High Positive byGC/MS (Greaterthan +50%)</td></tr><tr><td rowspan=2 colspan=1>Viewer A</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer B</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer C</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr></table>

# Dip Card Format

<table><tr><td rowspan=1 colspan=2>Wondfo Result</td><td rowspan=1 colspan=1>Drug-free</td><td rowspan=1 colspan=1>Low Negative by C/MS(Less than -50%)</td><td rowspan=1 colspan=1>Near CutoffNegative byGC/MS(Between -50%and Cutoff)</td><td rowspan=1 colspan=1>Near CutoffPositive byGC/MS(Between theCutoff and +50%)</td><td rowspan=1 colspan=1>High Positive byGC/MS (Greaterthan +50%)</td></tr><tr><td rowspan=2 colspan=1>Viewer A</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>17 ·</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer B</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer C</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr></table>

Discordant Results of AMP 300   

<table><tr><td rowspan=1 colspan=1>Viewer</td><td rowspan=1 colspan=1>Sample Number</td><td rowspan=1 colspan=1>GC/MS Result</td><td rowspan=1 colspan=1>Cup Format ViewerResult</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>AMP3063</td><td rowspan=1 colspan=1>281</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>AMP3216</td><td rowspan=1 colspan=1>259</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>AMP3218</td><td rowspan=1 colspan=1>287</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>AMP3063</td><td rowspan=1 colspan=1>281</td><td rowspan=1 colspan=1>Positive</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Viewer</td><td rowspan=1 colspan=1>Sample Number</td><td rowspan=1 colspan=1>GC/MS Result</td><td rowspan=1 colspan=1>Dip Card FormatViewer Results</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>AMP3218</td><td rowspan=1 colspan=1>287</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>AMP3216</td><td rowspan=1 colspan=1>259</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>AMP3063</td><td rowspan=1 colspan=1>281</td><td rowspan=1 colspan=1>Positive</td></tr></table>

# MET 500:

# Cup Format

<table><tr><td rowspan=1 colspan=2>Wondfo Result</td><td rowspan=1 colspan=1>Drug-free</td><td rowspan=1 colspan=1>Low Negative byC/MS(Less than -50%)</td><td rowspan=1 colspan=1>Near CutoffNegative byC/MS(Between -50%and Cutoff)</td><td rowspan=1 colspan=1>Near CutoffPositive byGC/MS(Between theCutoff and +50%)</td><td rowspan=1 colspan=1>High Positive byGC/MS (Greaterthan +50%)</td></tr><tr><td rowspan=2 colspan=1>Viewer A</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>•     13</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer B</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>.0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer C</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr></table>

# Dip Card Format

<table><tr><td rowspan=1 colspan=2>Wondfo Result</td><td rowspan=1 colspan=1>Drug-free</td><td rowspan=1 colspan=1>Low Negative byGC/MS(Less than -50%)</td><td rowspan=1 colspan=1>Near CutoffNegative byGCMS(Between -50%and Cutoff)</td><td rowspan=1 colspan=1>Near CutoffPositive byGC/MS(Between theCutoff and +50%)</td><td rowspan=1 colspan=1>High Positive byGC/MS (Greaterthan +50%)</td></tr><tr><td rowspan=2 colspan=1>Viewer A</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer B</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer C</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr></table>

Discordant Results of MET 500   

<table><tr><td rowspan=1 colspan=1>Viewer</td><td rowspan=1 colspan=1>Sample Number</td><td rowspan=1 colspan=1>GC/MS Result</td><td rowspan=1 colspan=1>Cup Format ViewerResult</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>MET5061</td><td rowspan=1 colspan=1>478</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>MET5216</td><td rowspan=1 colspan=1>474</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>MET5063</td><td rowspan=1 colspan=1>499</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>MET5215</td><td rowspan=1 colspan=1>421</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>MET5061</td><td rowspan=1 colspan=1>478</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>MET5063</td><td rowspan=1 colspan=1>499</td><td rowspan=1 colspan=1>Positive</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Viewer</td><td rowspan=1 colspan=1>Sample Number</td><td rowspan=1 colspan=1>GC/MS Result</td><td rowspan=1 colspan=1>Dip Card FormatViewer Results</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>MET5063</td><td rowspan=1 colspan=1>499</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>MET5061</td><td rowspan=1 colspan=1>478</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>MET5061</td><td rowspan=1 colspan=1>478</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>MET5063</td><td rowspan=1 colspan=1>499</td><td rowspan=1 colspan=1>Positive</td></tr></table>

# 11.3. Clinical Studies

Not applicable

# 12. Conclusion

Based on the test principle and performance characteristics of the device, it's concluded that Wondfo Amphetamine Urine Test (AMP 300), Wondfo Methamphetamine Urine Test (MET 500) are substantially equivalent to the predicate devices.

# December 21, 2012

Guangzhou Wondfo Biotech Co., Ltd. LSI International Inc.   
c/o Joe Shia   
504 East Diamond Ave.   
Suite F   
Gaithersburg, MD 20878

Re: k122961 Trade/Device Name: Wondfo Amphetamine Urine Test (AMP 300) Wondfo Methamphetamine Urine Test (MET 500)

Regulation Number: 21 CFR 862.3100   
Regulation Name: Amphetamine Test System   
Regulatory Class: Class II   
Product Code: DKZ, LAF   
Dated: November 8, 2012   
Received: November 13, 2012

Dear Mr Shia:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class II (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical

device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostics and Radiological Health at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours, Carol CBenson for

Courtney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices In Vitro Diagnosticsand Radiological Health Center for Devices and Radiological Health

# Indications for Use

510(k) Number (if known): K122961

Device Name: Wondfo Amphetamine Urine Test (AMP 300) Wondfo Methamphetamine Urine Test (MET 500)

Indications for Use:

Wondfo Amphetamine Urine Test (AMP 300):

Wondfo Amphetamine Urine Test (AMP 300) is an immunochromatographic assay for the qualitative determination of d-Amphetamine in human urine at a cutoff concentration of $3 0 0 ~ \mathrm { n g / m L }$ . The test is available in a Dip Card format and a Cup format. This product is only intended for prescription use and is not intended for point-of-care use. For in vitro diagnostic use only.

The test provides only preliminary test results. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. GC/MS is the preferred confirmatory method. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary result is positive.

Wondfo Methamphetamine Urine Test (MET 500):

Wondfo Methamphetamine Urine Test (MET 500) is an immunochromatographic assay for the qualitative determination of $\mathbf { D } ( + )$ -Methamphetamine in human urine at a cutoff concentration of ${ 5 0 0 } \mathrm { n g / m L }$ . The test is available in a Dip Card format and a Cup format. This product is only intended for prescription use and is not intended for point-of-care use. For in vitro diagnostic use only.

Concurrence of CDRH, Office of In Vitro Diagnostics and Radiological Health (OIR)

Division SigntOff /   
Office of In Vitro Diagnostics and Radiological Health   
510(k) K127961

The test provides only preliminary test results. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. GC/MS is the preferred confirmatory method. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary result is positive.

Prescription Use X And/Or Over the Counter Use (21 CFR Part 801 Subpart D) (21 CFR Part 801 Subpart C)

Concurrence of CDRH, Office of In Vitro Diagnostics and Radiological Health (OIR)

![](images/155ae88e037a51e5b5ae1c564e14e3251803b2ada9aa6ff61aadf1534235667a.jpg)

Division Sign-Off   
Office of In Vitro Diagnostics and Radiological Health   
510(k) K122961

# Page 2 of 2